MagicMed Industries Announces the Establishment of Psilocybin-Derivatives Portfolio and Launch of Candidate Selection Program
MagicMed Industries Inc. (CSE: MGIC reserved) (" MagicMed" or the " Company") announced today that it has completed the establishment of the psilocybin-derivatives patent portfolio of the Psybrary TM and the launch of the Candidate Selection program. The Psybrary TM is a proprietary physical and knowledgebase collection of novel psychedelic-derivative drug candidates, manufacturing methods, pharmacological data, and patent filings that protect all of the above. MagicMed's Chief Scientific Officer, Dr. Peter Facchini, stated "Our psilocybin-derivatives portfolio, which also captures dimet...
Source: prnewswire.com